24小时热门版块排行榜    

查看: 1676  |  回复: 5

water_still

新虫 (小有名气)

[求助] 回修后被拒,能重新投稿吗? 已有1人参与

投Frontiers in immunology杂志,经过Interactive Review后,一审稿人withdrew,另一审稿人同意发表,结果编辑拒稿,拒稿信很官方:

Dear XXX,

Unfortunately, I have to inform you that your manuscript "XXXXXX" cannot be accepted for publication in Frontiers in Immunology, section Vaccines and Molecular Therapeutics.

The reason for this decision is:

The content of this manuscript does not meet the standards of rigor required by the journal to be considered for publication.

The overall assessment by peer reviewers and the editorial panel is that this manuscript contributes little to the field beyond the work reported in the authors prior publications and that the revisions made during the interactive review process are not substantial enough to address the concerns raised upon review.

You can access the review forum with the manuscript and comments using the following link:

XXXXX

Please note that should you choose to resubmit your manuscript to a Frontiers Journal/Specialty, it must be accompanied by a statement of resubmission inserted in the relevant textbox of the submission platform, and addressing the reasons for previous rejection or withdrawal, as well as highlighting any subsequent changes.

With best regards,

Denise Doolan

Specialty Chief Editor,

请问最后一段是编辑给我了重投的机会了吗?能不能重新投稿?重新投稿速度快吗?非常感谢!
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

791825715

捐助贵宾 (著名写手)

编辑没有主观或者鼓励你重投,但你可以选择重投

发自小木虫IOS客户端
2楼2020-06-20 13:15:28
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

易晓伟

铜虫 (正式写手)

须知天狭窄,不及井中宽!!!
3楼2020-06-20 13:17:40
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

匿名

用户注销 (小有名气)

本帖仅楼主可见
4楼2020-06-20 15:44:59
已阅   申请SEPI   回复此楼   编辑   查看我的主页

smhpy

金虫 (著名写手)

鼓励重投是会明确说鼓励的,而且会给期限

发自小木虫Android客户端
5楼2020-06-20 15:49:38
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

bobvan

至尊木虫 (文坛精英)

【答案】应助回帖

★ ★ ★ ★ ★
感谢参与,应助指数 +1
water_still: 金币+5, ★★★很有帮助 2020-06-22 10:32:36
允许重投,但需要说明先前的投稿纪录(为什么被拒,作了哪些改进)
6楼2020-06-21 01:37:52
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 water_still 的主题更新
信息提示
请填处理意见